Clinical Trial Update: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures [Phase 2]

View source ↗

Summary

Phase 2 double-blind, randomized, placebo-controlled trial evaluating YKP3089 as adjunctive therapy for partial onset seizures; results were posted in 2022 afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy
• Partial-onset Seizures

Drugs mentioned

• YKP3089

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Partial Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2022-04-29